Herbert Loong, Advisor at Greater Bay Area International Clinical Trial Institute, and Steering Committee Member at Lung Cancer Policy Network, shared a post on LinkedIn:
“Throwback to the International Association for the Study of Lung Cancer and ESMO – European Society for Medical Oncology, ELCC 2026 in Copenhagen, where we presented our real-world report on late-presenting adverse events and management strategies in patients on selective RET inhibitors.”
Other articles about RET Inhibitor on OncoDaily.